Research-backed Irish med-tech startup, NeuroBell, has recently secured €2.1 million in investment funding. Led by Furthr Venture Capital, Atlantic Bridge, and HBAN MedTech Syndicate, the funding round also saw participation from Enterprise Ireland and other private investors. This investment will enable NeuroBell to separate from University College Cork (UCC) and launch its groundbreaking technology for the real-time and accurate detection of seizures in newborns requiring additional care.
NeuroBell’s innovative solution utilizes artificial intelligence (AI) to assist medical professionals in swiftly diagnosing abnormal brain activity in newborns. By enabling early intervention, this technology bears the potential to significantly improve outcomes for infants in need. The startup was established by a team of experts, including Dr. Mark O’Sullivan, Dr. Alison O’Shea, and Colm Murphy. It originally emerged as a spin-out from both UCC and the Irish Centre for Maternal and Child Health Research (Infant).
The objective of NeuroBell is to address a critical gap that currently exists in the availability and accuracy of technologies used for detecting seizures in newborns admitted to neonatal intensive care units (NICUs). Timely detection of seizures is vital for prompt interventions in babies with brain injuries, which can potentially reduce the long-term impact of conditions such as epilepsy and cerebral palsy.
Unlike large machines with limited availability, NeuroBell has developed a wireless, pocket-sized brain monitor embedded with edge AI technology. This user-friendly device allows for the detection of seizures in NICU patients, facilitating routine monitoring across various hospital settings without requiring specialized expertise.
Looking ahead, NeuroBell is committed to obtaining FDA approval to launch its revolutionary device in the US market this year, with plans to subsequently introduce it to the European market. The latest funding will further support the startup’s product development, additional clinical trials, and team expansion. The company anticipates creating 12 new jobs in engineering, quality assurance, and business development by next year. With its goal of providing gold-standard brain monitoring to patients in all medical settings, NeuroBell is poised to revolutionize the field of newborn care.
The source of the article is from the blog myshopsguide.com